Navigation Links
Orexigen(R) Therapeutics Announces First of Four Phase 3 Trials of Contrave(R) Meets Co-Primary and Key Secondary Endpoints
Date:1/8/2009

ected food craving measures.

The overall discontinuation rate due to adverse events was 25.9% for patients taking Contrave versus 13.0% for those taking placebo. The most frequently observed adverse events leading to discontinuation for patients on study drug were nausea, urticaria (hives) and anxiety. The discontinuation rate due to nausea was 4.6%, an improvement over the 11.1% discontinuation rate seen in the Phase 2 trial (NB-201) which utilized the immediate release formulation of naltrexone as opposed to the proprietary SR formulation used in this trial. The most frequently observed treatment-emergent adverse events for patients on study drug were nausea, headache, constipation and dizziness.

"The results show that Contrave provided obese patients with clinically significant weight loss sustained over a one year period while also improving markers associated with cardiovascular disease," said Dr. Xavier Pi-Sunyer, a lead investigator for the study and Chief of Endocrinology at St. Luke's-Roosevelt Hospital/Professor of Medicine at Columbia University. "This study also showed that Contrave was generally well tolerated by patients, which is important in terms of patient compliance, especially since treating obesity is often a long-term endeavor."

The Company has scheduled a conference call at 5:00 pm Eastern Time to discuss further details from this trial. The live call may be accessed by calling 877-317-6701(domestic) 412-317-6701 (international); meeting code: 007 4510. The webcast can be accessed live on the investor relations section of the Company's web site at http://www.orexigen.com and will be archived for 14 days following the call. Additional findings will be presented at the JPMorgan Healthcare Conference on January 12, 2009 at 8:00 am (PST) in San Francisco, California.

About Obesity

Obesi
'/>"/>

SOURCE Orexigen Therapeutics, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7

Related biology technology :

1. Orexigen(R) Therapeutics Issued a Key Fourth U.S. Patent on Contrave(R)
2. Orexigen(R) Therapeutics Announces Third Quarter 2008 Financial Results
3. Orexigen(R) Therapeutics Initiates First Clinical Trial of OREX-003 for the Mitigation of Antipsychotic-Associated Weight Gain
4. Orexigen(R) Therapeutics Appoints Dennis Kim, M.D., as Senior Vice President, Head of Obesity and Metabolic Disorders
5. Orexigen(R) Therapeutics to Present at Upcoming Investor Conferences
6. Orexigen(R) Therapeutics Schedules Webcast Discussion of Financial Results for the Second Quarter Ended June 30, 2008
7. OREXIGEN(R) Therapeutics Receives Notice of Allowance for U.S. Patent Covering the Composition of Matter in OREX-003
8. InteKrin Therapeutics to Present at the 27th Annual JP Morgan Healthcare Conference on Tuesday, January 13
9. Aegera Therapeutics Initiates A Randomized Phase 2 Combination Study of AEG35156 for 1st Line Treatment of Non-Small Cell Lung Cancer
10. Amicus Therapeutics Adds Sol J. Barer, Ph.D. to Board of Directors
11. Cell Therapeutics Announces Receipt of NASDAQ Panel Decision to Transfer to NASDAQ Capital Market
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/19/2014)... (PRWEB) October 20, 2014 ... Industry Meeting (ABIM). ABIM will take ... More information about ABIM 2014 is now ... , Delegates representing companies and organizations from ... and obtain information on the latest products ...
(Date:10/19/2014)... 2014 The Asia-Pacific Bromine Market ... Asia-Pacific with analysis and forecast of revenue. , ... Bromine Market report, to get an idea of ... glimpse of the segmentation in the Asia-Pacific bromine ... figures. , http://www.micromarketmonitor.com/market/asia-pacific-bromine-6741503144.html , Bromine ...
(Date:10/19/2014)... Asia-Pacific Speech Analytics market report defines and segments the ... of revenue. This market is estimated to grow from ... at a Compound Annual Growth Rate (CAGR) of 23.9% ... of the Asia-Pacific Speech Analytics market report to get ... provides a glimpse of the segmentation in the market, ...
(Date:10/19/2014)... Orthopedic braces and support systems report defines and segments the ... The Orthopedic braces and support systems market in Asia is ... a developing CAGR of 4.4% from 2013 to 2018. , ... support systems market, to get an idea of the in-depth ... of orthopedic braces and support systems market in the same ...
Breaking Biology Technology:The Asia-Pacific Bromine Market is estimated to grow to $4,080.1 million by 2018 - New Report by MicroMarket Monitor 2The Asia-Pacific Bromine Market is estimated to grow to $4,080.1 million by 2018 - New Report by MicroMarket Monitor 3The Asia-Pacific Speech Analytics market is estimated to reach $208 million by 2019 - New Report by MicroMarket Monitor 2The Asia-Pacific Speech Analytics market is estimated to reach $208 million by 2019 - New Report by MicroMarket Monitor 3The Asia-Pacific Speech Analytics market is estimated to reach $208 million by 2019 - New Report by MicroMarket Monitor 4The Asian Orthopedic braces and support systems market is estimated to grow to around $416.5 million by 2018 - New Report by MicroMarket Monitor 2The Asian Orthopedic braces and support systems market is estimated to grow to around $416.5 million by 2018 - New Report by MicroMarket Monitor 3The Asian Orthopedic braces and support systems market is estimated to grow to around $416.5 million by 2018 - New Report by MicroMarket Monitor 4
... THRM ), a leader in non-invasive tissue ... will present at the 2008 Thomas Weisel,Partners Healthcare ... The,Company,s presentation is scheduled for Wednesday, September 3, ... President and Chief,Executive Officer of Thermage, will review ...
... 27 The Board of,Directors, meeting today under the chairmanship of Albert Saporta, approved,STALLERGENES, half year consolidated financial statements:, (EUR millions) ... 08/07 ... of % ... sales change, Sales ...
... Aug. 27 MichBio, the association for,Michigan,s biosciences ... Showcase to its program on day one of ... the Rock Financial ShowPlace Novi, MI. The,event will ... introduce,their bioscience technologies and emerging companies to an ...
Cached Biology Technology:Stallergenes: First Half Year 2008: A 19% Increase in Operating Profit and Net Profit 2Stallergenes: First Half Year 2008: A 19% Increase in Operating Profit and Net Profit 3Start-Up and Emerging Biotech Companies Will Tell Their Stories at Biosciences Showcase Planned for MichBio Expo 2
(Date:10/17/2014)... Why do male ... reproduce? And why are there two sexes anyway? These and ... the research journal Molecular Human Reproduction published today ... University Bielefeld has compiled this special issue on sperm competition. ... copulate with several males in quick succession – chimpanzees are ...
(Date:10/16/2014)... human body. Battles are won, lost or sometimes ... stalemate—known as tumor dormancy—can last up to 25 ... is poorly understood. , A new computational ... a Professor of Chemistry at Princeton University, may ... the switch to a malignant state. Published today ...
(Date:10/16/2014)... have challenged conventional thinking on how the bowel lining ... for how bowel cancer starts. , The researchers produced ... regenerating the ,crypts, that are a feature of the ... in bowel cancer development, a controversial finding as scientists ... Using 3D imaging technologies, Dr Chin Wee Tan and ...
Breaking Biology News(10 mins):Sperm wars 2Modeling tumor dormancy 2Cryptic clues drive new theory of bowel cancer development 2
... -- The Society of American Foresters has named Louisiana ... Director A. Gordon Holley as its 2012 Carl Alwin ... the 2012 Society of Foresters National Convention held Oct. ... outstanding performance in the field of forestry education. This ...
... . . . U.S. Forest Service and ... levels of ozone may amplify the impacts of higher ... and other water bodies. Such effects could potentially reduce ... in the southeastern United States. Using data on atmospheric ...
... A team led by researchers at the University of ... "superbug" methicillin-resistant Staphylococcus aureus (MRSA) is prevalent ... well known for causing difficult-to-treat and potentially fatal bacterial ... it has also been infecting otherwise healthy people in ...
Cached Biology News:Louisiana Tech University professor earns national honor from Society of American Foresters 2November 2012 story tips 2Superbug MRSA identified in US wastewater treatment plants 2
Shake 'n' Stack oven - New Model (includes 10 bottle capacity rotisserie, adjustable feet, drip tray, manual)...
... The Neural Stem Cell Expansion Kit - ... in vitro NSC expansion as a monolayer ... specially formulated N-2 Plus Media Supplement, which has ... K.K. et al . (1996) Genes & ...
... Description: Topoisomerase I relaxes both positively and negatively ... of phosphodiester bonds (1,2) . Relaxing supercoiled DNA ... by a single nucleotide pair by gel electrophoresis ... absence of Mn 2+ and can be ...
... template-directed polymerization of nucleotides into duplex DNA ... possesses a 3?5 exonuclease activity or "proofreading" ... DNA replication, and also contains a 5?3 ... replace nucleotides in the growing strand of ...
Biology Products: